NAMS: NewAmsterdam Pharma Company Short-Term Debt

Symbol and logo of brand NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma brings together elite cardiologists within a flexible, bureaucracy-free structure. Monitoring current debt on the GURU.Markets terminal chart shows that 0.00 serves as the current parameter value. Lipidologists support the mission through European grants; however, revenue shortfalls and R&D expenses are leading to capital depletion and a search for new investments.

NAMS (NewAmsterdam Pharma Company) Company Short-Term Debts history from 06/21/2023 to 10/31/2026

NAMS (NewAmsterdam Pharma Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart NewAmsterdam Pharma Company N.V.|NAMS - Fair Value Consensus
- market capitalization information:
Market Value NewAmsterdam Pharma Company N.V.|NAMS - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share NewAmsterdam Pharma|NAMS - Book Capitalization|Market Cap to Net Assets Ratio newamsterdampharma.com|NAMS - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity NewAmsterdam Pharma|NAMS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NewAmsterdam Pharma|NAMS - Company Cumulative Debt|Debt to Book Value NewAmsterdam Pharma Company N.V.|NAMS - Amount of Long-Term Liabilities|Company Short-Term Debts NewAmsterdam Pharma|Quick Ratio newamsterdampharma.com
- net income and valuation multiples indicators:
NAMS - Company Net Income
Basic company analysis:NewAmsterdam Pharma Company N.V. - NAMS
Mass-produced product of NewAmsterdam Pharma Corp

NewAmsterdam Pharma's development in cardiology requires significant investment, making liquidity control critical for maintaining its scientific standing. The dynamics of the company's current liabilities reflect the total volume of loans maturing within a year, allowing investors to assess the issuer's ability to service debt without compromising revenue growth rates or clinical trials.

Who NewAmsterdam Pharma competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Soleno SLNO|FOLD - Company Current Liabilities|89bio, Inc. - Company Short-Term Debts|Short-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|MTNB: Company Short-Term Indebtedness|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Galecto Inc|CTCX (Carmell Corp) - Company Current Liabilities|Company Current Liabilities Lumos Therapeutics|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Short-Term Debts radiuspharm.com